Literature DB >> 9475510

Developmental and regional alteration of kappa-opioid receptors in seizure-susceptible EL mouse brain.

T Kai1, H Onishi, S Koide, M Katayama, S Yamagami.   

Abstract

The binding of [3H]ethylketocyclazocine ([3H]EKC) under the suppression of mu and delta sites in the brain of EL mice (seizure-susceptible) was examined to determine the relationship between seizures and the dynorphinergic system. The density of kappa-opioid receptors in the cerebrum of adult EL mice during interictal periods significantly increased, without changes in apparent affinities, compared with that of adult ddY mice (seizure-nonsusceptible; the mother strain of EL). Subsequently, the binding of 0.8 nM [3H]EKC in 8 brain regions was examined in the 2 strains. The [3H]EKC binding in 25-day-old EL mice that had no seizures significantly increased in the hippocampus and amygdala. At the age of 50 days, EL mice displayed abortive seizures, and the number of kappa sites in EL mice was significantly greater in the hippocampus, amygdala and cerebral cortex. It was further shown that the binding of [3H]EKC in 150-day-old adult EL mice during interictal periods was markedly increased in the hippocampus, amygdala, cerebral cortex and striatum, compared with the corresponding regions in ddY mice. The up-regulation of kappa receptors in the EL mouse brain may result from deficits in endogenous dynorphins, which could be involved in the pathogenesis of seizure diathesis and seizure manifestations in the EL mouse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9475510     DOI: 10.1023/a:1022424707543

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  35 in total

1.  Distribution of GABA concentrations and GAD activities in the parietal cortex and the hippocampal CA1 in an El mouse.

Authors:  Y L Murashima; K Kasamo; J Suzuki
Journal:  Jpn J Psychiatry Neurol       Date:  1990-06

2.  U-54494A: a unique anticonvulsant related to kappa opioid agonists.

Authors:  P F VonVoigtlander; E D Hall; M C Ochoa; R A Lewis; H J Triezenberg
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

3.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

4.  Alteration of opioid receptors in seizure-susceptible El mouse brain.

Authors:  H Onishi; T Soma; S Yamagami; Y Kawakita
Journal:  Neurochem Res       Date:  1989-01       Impact factor: 3.996

5.  Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

Authors:  J R Gavin; J Roth; D M Neville; P de Meyts; D N Buell
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

6.  Effects of morphine and D-Ala2-D-Leu5-enkephalin in the seizure-susceptible El mouse.

Authors:  S Koide; H Onishi; S Yamagami; Y Kawakita
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

7.  Repeated electroconvulsive shock or chronic morphine treatment increases the number of 3H-D-Ala2,D-Leu5-enkephalin binding sites in rat brain membranes.

Authors:  J W Holaday; R J Hitzemann; J Curell; F C Tortella; G L Belenky
Journal:  Life Sci       Date:  1982 Nov 15-22       Impact factor: 5.037

8.  Similar anticonvulsant, but unique, behavioural effects of opioid agonists in the seizure-sensitive Mongolian gerbil.

Authors:  R J Lee; J G Bajorek; P Lomax
Journal:  Neuropharmacology       Date:  1984-05       Impact factor: 5.250

9.  Repeated electroconvulsive shock downregulates the opioid receptors in rat brain.

Authors:  Y Nakata; K J Chang; C L Mitchell; J S Hong
Journal:  Brain Res       Date:  1985-10-28       Impact factor: 3.252

Review 10.  Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems.

Authors:  H Frenk
Journal:  Brain Res       Date:  1983-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.